World Antibiotics Overview & Outlook 2017-2018 to 2022: The Quest for New Super Drugs - Technologies, Markets, Competitors and Opportunities - ResearchAndMarkets.com

DUBLIN--()--The "Antibiotics: the Quest for New Super Drugs: Technologies, Markets, Competitors and Opportunities: 2017-2022 Analysis and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Today, antibiotics are used routinely to treat and prevent infection. However, drug- and multi-drug-resistant bacterial strains pose a serious threat in the clinical setting as they directly contribute to an increase in morbidity and mortality, as compared to the underlying disease itself.

Due to antibiotic resistance, new antibiotic super drugs are desperately needed to fight infections like MRSA, CRE, ESBLs and C. difficile. And that is beyond dealing with diseases like drug-resistant Gonorrhea, which affects an estimated 78 million people globally, or TB, which affects 10 million people worldwide, or even the 1 million+ people in the U.S. who get hospitalized with Pneumonia annually. Or bioweapons like Anthrax. Unfortunately, it is hard to discover new antibiotics.

Further compounding the problem, from approximately 20 traditional pharmaceutical companies investing in antibiotic research in the 1980s, there are now only five with significant active internal research programs. As a result, most novel antibiotic development is now being conducted by small biotech companies.

Over the last few years there has been a growing realization among the various stakeholders (Industry players, governments, authorities and medical charities) that something needs to be done to address the issues impacting antibiotic R&D, and avoid the looming socio-economic burden of antimicrobial resistance.

Current antibiotics work now, for the most part. But if an epidemic of one of the multi-drug-resistant strains rapidly spreading across the globe happens, it will be too late to start funding the discovery of new antibiotics. The need to invest is now, so there are options when the inevitable next black death appears. This report addresses these issues.

Specifically, it provides:

  • Antibiotics Overview
  • Quest for Super Antibiotic Drugs
  • Antibiotics Market
  • Company Profiles
  • In addition to 37 company profiles, the report contains 14 tables and 62 figures

Companies Featured

  • Achaogen Inc
  • Actelion Ltd.
  • AstaZeneca plc
  • Atox Bio
  • Basilea Pharmaceutica AG
  • Cempra Inc
  • CrystalGenomics, Inc.
  • Cubist Pharmaceuticals, Inc.
  • Destiny Pharma Ltd.
  • Dong Wha Pharmaceuticals
  • Durata Therapeutics, Inc.
  • Eisai Co., Ltd.
  • Furiex Pharmaceuticals, Inc.
  • GlaxoSmithKline, Plc.
  • Insmed Incorporated
  • Merck & Co., Inc
  • MerLion Pharmaceuticals Pte Ltd
  • MicuRx Pharmaceuticals, Inc.
  • Nabriva Therapeutics AG
  • Novartis AG
  • Osel Inc
  • Otonomy, Inc
  • Otsuka Pharmaceutical Co. Ltd.
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc
  • Rebiotix, Inc
  • Roche Holding AG
  • Savara Pharmaceuticals
  • Sequella, Incorporated
  • Seres Therapeutics, Inc.
  • Summit, plc
  • TaiGen Biotechnology Co., Ltd.
  • Tetraphase Pharmaceuticals, Inc
  • The Medicines Company
  • Theravance Biopharma Inc

Key Topics Covered

1. Introduction

2. Antibiotics Overview

3. Quest For Super Antibiotic Drugs

4. Antibiotics Market

5. Company Profiles

Appendix 1: Antibiotic Classes

Appendix 2: Regulation

List of Tables

List of Figures

For more information about this report visit https://www.researchandmarkets.com/research/jml9bw/world_antibiotics?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Antibiotics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Antibiotics